MFAP5 blockade can inhibit fibrosis and enhance chemosensitivity in ovarian and pancreatic cancer (Yeung et al., 2019), and can promote basal-like breast cancer progression by activating epithelial-to-mesenchymal transition (Wu et al., 2019). Here, MFAP5 is linked to familial pancreatic carcinoma.